

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B44; Cw5, Cw7; DR15, DR17; DQ2, DQ6

Summary of Results					Summary of Results				
Total tested	50	50	50	49	34	34	34	34	
Positive	1	1	0	0	1	0	0	0	
Negative	49	49	50	49	33	34	34	34	
Not Tested	4	4	4	5	3	3	3	3	
% Positive	2.0%	2.0%	0.0%	0.0%	2.9%	0.0%	0.0%	0.0%	
% Negative	98.0%	98.0%	100.0%	100.0%	97.1%	100.0%	100.0%	100.0%	
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Cw4, Cw6	A24	B51	B17					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	NT	NT	NT	NT	NT	NT	NT	NT	Internal controls non-satisfactory
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
119	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
128	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
136	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
139	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
145	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
154	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
159	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
163	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
174	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
189	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
197	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
235	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
238	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
243	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Negative	Positive	Negative	NT	Negative	Negative	Negative	Negative	
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		pre C'	post C'	
112	NT	NT	NT	NT	NT	NT	NT	NT	05-Jun	06-Jun	Yes		No	98		Cedarlane	60	120	Stain fix
114	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	Yes			One Lambda	30	60	AO/EB
116	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	No	95		Cedarlane	20	60	AO/EB
117									05-Jun	06-Jun	Yes		No	70		Pel-freeze	60	120	Eosin
119	4	1	1	1	2	1	1	1	04-Jun	05-Jun	Yes		No	90		Biorad	30	60	Eosin
120	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	100		Servbio	30	60	AO/EB
126									04-Jun	04-Jun		Yes	Yes	100		Cedarlane	30	40	AO/EB
128	1	1	1	1					04-Jun	04-Jun	Yes		No	98		One Lambda	45	90	Stain fix
136	1	1	1	1					04-Jun	04-Jun			Yes	95		In-House	60	60	
139									05-Jun	06-Jun	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	1	1	1	1					06-Jun	06-Jun		Yes	Yes	95		Cedarlane	30	60	Eosin
145									04-Jun	06-Jun		Yes	Yes	100		Invitrogen	45	45	AO/EB
147	1	1	1	1	1	1	1	1	05-Jun	05-Jun		Yes	Yes	100		In-House	30	60	Fluoroquench
149									05-Jun	06-Jun	Yes			90			60	60	Eosin
154	1	1	1	1					04-Jun	05-Jun		Yes	No	99		Cedarlane	30	60	Eosin
159	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	95		In-House	30	60	Fluoroquench
162									05-Jun	05-Jun		Yes	Yes	100		Cedarlane	60	60	
163	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	98		Cedarlane	30	60	Fluoroquench
164									04-Jun	04-Jun		Yes	Yes	90		Servbio	45	90	AO/EB
169	1	1	1	1	1	1	1	1	05-Jun	06-Jun		Yes	Yes	99		One Lambda	35	75	Fluoroquench
174									07-Jun	09-Jun	Yes			94		One Lambda	60	120	Eosin
181	1	1	1	1					04-Jun	04-Jun	Yes		No	100		Cedarlane	30	45	EB
186	0	0	0	0	0	0	0	0	04-Jun	04-Jun		Yes	Yes	99		Invitrogen	30	60	EB
189	1	1	1	1					04-Jun	05-Jun	Yes		No	90		Biorad	40	40	AO/EB
190	<5%	<5%	<5%	<5%	<5%	<5%	<5%	<5%	04-Jun	05-Jun		Yes	Yes	98		Cedarlane			Fluoroquench
193	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	No	100		Cedarlane	30	60	Stain fix
194	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	Yes	100		In-House	30	45	Fluoroquench
195	1	1	1	1	1	1	1	1	06-Jun	06-Jun	Yes		No	80		Invitrogen	30	60	Fluoroquench
197																			
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	No	95		Cedarlane	45	90	Fluoroquench
206									04-Jun	04-Jun		Yes	Yes	100		Cedarlane	30	45	Fluoroquench
209									04-Jun	05-Jun	Yes		No	98		Ingen	30	60	Fluoroquench
210	0	0	0	0	0	0	0	0	05-Jun	05-Jun		Yes	Yes	100		Biorad	30	60	
216	1	1	1	2					09-Jun	09-Jun	Yes		No	95		Biorad	30	60	
223	1	1	1	1					10-Jun	10-Jun		Yes	Yes	95		Biorad	45	60	AO/EB
227									04-Jun	04-Jun		Yes	Yes	98		Immucor	30	60	Fluoroquench
229									05-Jun	05-Jun	Yes		No	90		Cedarlane	30	60	
232	0	0	0	0					06-May	06-May	Yes		No	90		Biotest	45	60	Fluoroquench
235	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes		No	85		Biorad	30	60	Eosin
238	1	1	1	2	1	1	1	1	04-Jun	05-Jun		Yes	Yes	95	95	Invitrogen	45	90	Fluoroquench
243	2	2	2	2					04-Jun	05-Jun	Yes		Yes	90	80	Biorad	30	60	Fluoroquench
245	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes	Yes	Yes	100	100	BAG	30	60	AO/EB
252	1-2	1-2	1-2	1-2	1-2	1-2	1-2	1-2	05-Jun	05-Jun	Yes		No	50		One Lambda	30	60	
259									06-Jun	06-Jun	Yes	Yes	Yes	60	75	Biorad	30	60	PI/AO
260									05-Jun	05-Jun		Yes	Yes	90		Biorad	30	60	AO/EB
262									04-Jun	04-Jun	Yes	Yes	Yes	95		Invitrogen	30	60	Eosin
268	1	1	1	1	1	1	1	1	03-Jun	03-Jun		Yes	No	96		Gentrak	30	60	AO/EB
271	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	98		Cedarlane	40	60	AO/EB
293									05-Jun	05-Jun		Yes	Yes	80		Invitrogen	60	120	Eosin
294	0	0	0	0	0	0	0	0	04-Jun	05-Jun		Yes	Yes	95		Pel-Freeze	30	30	Fluoroquench
297	1	1	1	1	1	1	1	1	04-Jun	05-Jun	Yes	Yes	Yes	90	90	Cedarlane	30	60	AO/EB
311									04-Jun	05-Jun			Yes			Servbio	30	60	Fluoroquench

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B44; Cw5, Cw7; DR15, DR17; DQ2, DQ6

Summary of Results					Summary of Results				
Total tested	35	35	35	33	30	29	29	28	
Positive	13	1	1	22	2	1	1	3	
Negative	22	34	34	11	28	28	28	25	
Not Tested	5	5	5	7	2	2	2	3	
% Positive	37.1%	2.9%	2.9%	66.7%	6.7%	3.4%	3.4%	10.7%	
% Negative	62.9%	97.1%	97.1%	33.3%	93.3%	96.6%	96.6%	89.3%	
Consensus	Not Assessed	Negative	Negative	Not Assessed	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Cw4, Cw6	A24	B51	B17					
Lab No.	Serum 1	Without DTT			With DTT (Not assessed)				Comments
		Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
120	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Positive					
139	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
145	Positive	Negative	Negative	Negative					
147	Positive	Positive	Positive	Positive	Negative	Positive	Positive	Positive	
154	Negative	Negative	Negative	Positive					
159	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
162	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
163	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Negative	Negative	Positive					
186	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
190	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
195	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
197	NT	NT	NT	NT					
202	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
204	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
206	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	NT	NT	NT	NT					Not tested due to low viability of B-cells
227	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Not tested due to technical failure
238	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
243	NT	NT	NT	NT					Inconclusive results
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Negative	Negative	Negative	NT					
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
284	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
311	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes		One Lambda	30	60	AO/EB
120	2	1	1	6	1	1	1	1	04-Jun	05-Jun	Yes	100	Servibio	30	60	AO/EB
126				50%					04-Jun	04-Jun	Yes	100	Cedarlane	30	40	AO/EB
139	4			6					05-Jun	06-Jun	Yes	90	Cedarlane	30	60	Eosin
145	6-8								04-Jun	06-Jun	Yes	90	Invitrogen	45	45	AO/EB
147	4	4	6	8	1	4	6	6	05-Jun	05-Jun	Yes	100	In-House	30	60	Fluoroquen
154		1	1	6					04-Jun	05-Jun	No	90	Cedarlane	30	60	Eosin
159	4	1	1	6	1	1	1	1	04-Jun	05-Jun	Yes	95	In-House	30	60	
162	1:4			1:4					05-Jun	05-Jun	Yes	100	Cedarlane	60	60	
163	1	1	1	4	1	1	1	1	04-Jun	05-Jun	Yes	98	Cedarlane	30	60	Fluoroquen
164									04-Jun	04-Jun	Yes	90	Servibio	45	90	AO/EB
169	1	1	1	1	1	1	1	1	05-Jun	06-Jun	Yes	99		35	75	Fluoroquen
181	1	1	1	6					04-Jun	04-Jun	Yes	100	Cedarlane	30	45	EB
186	2	0	0	4	0	0	0	0	04-Jun	04-Jun	Yes	99	Invitrogen	30	60	EB
190	10%	10%	10%	30%	20%	20%	20%	30%	04-Jun	05-Jun	Yes	90	Cedarlane	30	60	Fluoroquen
193	1	1	1	4	1	1	1	1	04-Jun	04-Jun	Yes	90	Cedarlane	30	60	Hb/PI
194	1	1	1	6	1	1	1	1	04-Jun	04-Jun	Yes	100	In-House	30	45	Fluoroquen
195	8	2	1	6	2	2	2	2	06-Jun	06-Jun	Yes	80	Invitrogen	60	90	Fluoroquen
197																
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	4	1	1	6	4	1	1	4	04-Jun	05-Jun	Yes	85	Cedarlane	45	90	Fluoroquen
206				4					04-Jun	04-Jun	Yes	100	Cedarlane	30	45	Fluoroquen
209									04-Jun	05-Jun	Yes	98	Ingen	30	60	Fluoroquen
210	0	0	0	0	0	0	0	0	05-Jun	05-Jun	Yes	90	Biorad	30	60	
223	NT	NT	NT	NT					10-Jun	10-Jun	Yes	40	Biorad	45	60	EB/AO
227									04-Jun	04-Jun	Yes	98	Immucor	30	60	Fluoroquen
238	8	1	1	8	1	1	1	1	04-Jun	05-Jun	Yes	80	Invitrogen	45	90	Fluoroquen
243	NT	NT	NT	NT					04-Jun	05-Jun	Yes	80	Biorad	30	60	Fluoroquen
245	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes	100	BAG	30	45	AO/EB
252	1-2	1-2	1-2	1-2	1-2	1-2	1-2	1-2	05-Jun	05-Jun	Yes	30		30	60	
259									06-Jun	06-Jun	Yes	70	Biorad	30	60	PI/AO
260									05-Jun	05-Jun	Yes	80	Biorad	30	60	AO/EB
262	6								04-Jun	04-Jun	Yes		Invitrogen	60	90	Eosin
268	1	1	1	4	1	1	1	1	03-Jun	03-Jun	Yes	95	Gentrak	30	60	AO/EB
271	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	4	1	1	6	1	1	1	1	04-Jun	05-Jun	Yes	90	Cedarlane	40	60	AO/EB
293									05-Jun	05-Jun	Yes	60	Invitrogen	60	120	Eosin
294	0	0	0	0	0	0	0	0	04-Jun	05-Jun	Yes	90	Pel-Freeze	30	30	Fluoroquen
297	4	2	2	6	1	1	1	1	04-Jun	05-Jun	Yes	90	Cedarlane	30	60	AO/EB
311				6					04-Jun	05-Jun	Yes		Servibio	30	60	Fluoroquen

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate